Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PDcontrol

Financiado

Cerrado

Protein damage control regulation of toxic protein aggregation in aging associa...

Protein damage control regulation of toxic protein aggregation in aging associated neurodegenerative diseases The worldwide aging population will lead to a dramatic increase in the number of people with Alzheimer’s disease and other incurable age-related neurodegenerative diseases over the next few decades. By 2050 over 115 million are ex... ver más

30/11/2016

UNIVERSITAIR MEDIS...

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

ACADEMISCH ZIEKENHUIS GRONINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-11-30 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UNIVERSITAIR MEDISCH CENTRUM...

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

AGGREGATION Cellular protein damage control interactomic analyses of MO... 176K€ Cerrado

LATELIFEHEALTH Mapping the late life health promoting mechanisms in worms a... 1M€ Cerrado

BFU2013-47710-R PRIONES Y AGREGONES COMO INHIBIDORES DE START: UNA VIA AL EN... 351K€ Cerrado

PID2021-128408OB-I00 CONTROL DE LA PROTEOSTASIS DURANTE EL CICLO CELULAR Y EN CON... 218K€ Cerrado

BFU2016-80234-R AGREGADOS PROTEOTOXICOS, ALTERACIONES DEL CHAPEROMA Y DECLIV... 351K€ Cerrado

RTI2018-101491-A-I00 ESCANEADO EXHAUSTIVO DE MUTACIONES EN UN DOMINIO PRIONICO PA... 133K€ Cerrado

Líder del proyecto

ACADEMISCH ZIEKENHUIS GRONINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The worldwide aging population will lead to a dramatic increase in the number of people with Alzheimer’s disease and other incurable age-related neurodegenerative diseases over the next few decades. By 2050 over 115 million are expected to suffer from these devastating diseases. The major pathological hallmark of these disorders is the accumulation of aggregation-prone disease proteins in aggregates in the brain. To understand the disease mechanisms and to identify targets for treatment, I aim to uncover the cellular pathways that regulate disease-protein toxicity and aggregation (proteotoxicity). Opening up such exciting new avenues for research is our recent identification of a modifier of aggregation, which we named MOAG-4, as a general regulator of age-related proteotoxicity in worm (C. elegans) models for neurodegenerative diseases. MOAG-4 and its human counterpart SERF act independently of classical pathways that degrade proteins or prevent their aggregation, but their molecular role remains to be determined. I hypothesize that MOAG-4/SERF represents a new regulatory pathway of age-related proteotoxicity in neurodegenerative diseases. With an ERC starting grant, I will uncover the pathway in which MOAG-4/SERF is operating, establish the mechanism by which the pathway regulates proteotoxicity, establish the evolutionarily conservation of the pathway in human cells, and establish its potential as a therapeutic target in patient-derived cells. By combining the power of C. elegans genetics with the development of cell-biological tools to visualize and monitor aggregation and toxicity in living and aging worms and in patient-derived cells, we will be at the forefront of providing new insights into disease-mechanisms. Our discoveries will offer new starting points for research and for the development of therapeutic interventions in the early molecular events of aging-associated neurodegenerative diseases.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores